Literature DB >> 8330043

Effects of apomorphine and L-dopa on the parkinsonian bladder.

B Aranda1, P Cramer.   

Abstract

Neurogenic bladder frequently occurs in Parkinson's disease. Detrusor hyperreflexia is a consequence of nigrostriatal dopamine depletion, whereas the cause of hyporeflexia remains unclear. We compared the results of cystometry and urethral profilometry with and without apomorphine (and L dopa) in 12 idiopathic parkinsonians with urinary disorders free of dopaminergic treatment. Whereas hyperreflexic patients improved with apomorphine, and to a lesser extent with L dopa, these drugs had no effect on hyporeflexic patients. These results confirm the role of dopaminergic lesions in the occurrence of bladder hyperreflexia and the possible implication of nondopaminergic lesions in the occurrence of hyporeflexia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8330043     DOI: 10.1002/nau.1930120302

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  18 in total

1.  Spinal cord involvement in Lewy body-related α-synucleinopathies.

Authors:  Raffaele Nardone; Yvonne Höller; Francesco Brigo; Viviana Versace; Luca Sebastianelli; Cristina Florea; Kerstin Schwenker; Stefan Golaszewski; Leopold Saltuari; Eugen Trinka
Journal:  J Spinal Cord Med       Date:  2019-01-08       Impact factor: 1.985

Review 2.  Neural control of the lower urinary tract.

Authors:  William C de Groat; Derek Griffiths; Naoki Yoshimura
Journal:  Compr Physiol       Date:  2015-01       Impact factor: 9.090

Review 3.  Urinary tract dysfunction in Parkinson's disease: a review.

Authors:  Lehana Yeo; Rajindra Singh; Mohan Gundeti; Jayanta M Barua; Junaid Masood
Journal:  Int Urol Nephrol       Date:  2011-05-07       Impact factor: 2.370

4.  Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease.

Authors:  Nir Giladi; Andreas Fichtner; Werner Poewe; Babak Boroojerdi
Journal:  J Neural Transm (Vienna)       Date:  2010-11-16       Impact factor: 3.575

Review 5.  Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.

Authors:  Eva Schaeffer; Daniela Berg
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

6.  Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy.

Authors:  R Sakakibara; T Hattori; T Uchiyama; T Yamanishi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

7.  Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway.

Authors:  Naoki Yoshimura; Sadako Kuno; Michael B Chancellor; William C De Groat; Satoshi Seki
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

Review 8.  Bladder and bowel dysfunction in Parkinson's disease.

Authors:  R Sakakibara; T Uchiyama; T Yamanishi; K Shirai; T Hattori
Journal:  J Neural Transm (Vienna)       Date:  2008-03-10       Impact factor: 3.575

9.  Rotigotine Effects on Bladder Function in Patients with Parkinson's Disease.

Authors:  Livia Brusa; Filomena Petta; Giuseppe Farullo; Valerio Iacovelli; Viviana Ponzo; Cesare Iani; Paolo Stanzione; Enrico Finazzi Agró
Journal:  Mov Disord Clin Pract       Date:  2017-04-19

Review 10.  Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage?

Authors:  Amit Batla; Véronique Phé; Lorenzo De Min; Jalesh N Panicker
Journal:  Mov Disord Clin Pract       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.